The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc

NEW YORK, NY / NewsDirect / March 11th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of Petros Pharmaceuticals Inc a company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs.

Petros Pharmaceuticals Inc (NASDAQ: PTPI) recent news about their drug candidate STENDRA® (avanafil) has piqued the interest of biotech growth investors.

Best Growth Stock's full report breaks through the noise and offers an extensive comprehensive analysis of Petros Pharma’s potential catalysts, share structure, potential outcomes from the FDA decision for STENDRA® (avanafil), and much more.

Access this full analysis free: https://bestgrowthstocks.com/access-ptpi-analysis/

(If you cannot click the link above, copy and paste to your browser may be required)

Access this full analysis free: https://bestgrowthstocks.com/access-ptpi-analysis/

(If you cannot click the link above, copy and paste to your browser may be required)

About Petros Pharmaceuticals

Petros Pharmaceuticals is committed to the goal of becoming a leading innovator in the emerging self-care market driving expanded access to key prescription pharmaceuticals as Over-the-Counter treatment options. Currently, Petros is pursuing increased access for its flagship prescription ED therapy, STENDRA, via potential OTC designation. If ultimately approved by the FDA for OTC access, STENDRA may be the first in its class to achieve this marketing status, also establishing company know-how as a proven platform for other prospective prescription therapeutics.

About Best Growth Stocks

Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions.

Contact Details

Best Growth Stocks

Steve Macalbry

Editor@bestgrowthstocks.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.